Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(tion intramuscular vaccine program desig...),Health

vaccinate the elderly against seasonal influenza. Filing for approval

in the United States is scheduled for the second quarter of 2008.

-- The phase II cell culture based vaccine program. A long-term alliance

agreement has been signed with Lonza for industrial-scale production.

-- In the field of preparedness for pandemic influenza, sanofi pasteur

received FDA approval in 2007 for the first H5N1 vaccine to be

registered in the United States, and has also filed for approval of a

vaccine of the same type in Europe. Encouraging results have also been

obtained for an optimized low-dose H5NI vaccine using a new adjuvant.

The Menactra(R) Toddler program to develop a meningococcal meningitis vaccine for very young children is ongoing, with 2009 the target date for filing. The most recent information request by the FDA on Pentacel, was provided at the end of 2007.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE: SNY).

Contacts: Jean-Marc Podvin, jean-marc.podvin@sanofi-aventis.com, Phone: 33 1 53 77 42 23

Forward-Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intent
'/>"/>